Guilin Sanjin Pharmaceutical Co., Ltd. (SHE:002275)
China
· Delayed Price · Currency is CNY 13.65
-0.06 (-0.44%)
Apr 30, 2025, 3:04 PM CST
SHE:002275 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 2,194 | 2,168 | 1,954 | 1,739 | 1,564 | Upgrade
|
| Other Revenue | - | 3.66 | 5.27 | 2.71 | 2.79 | Upgrade
|
| Revenue | 2,194 | 2,172 | 1,960 | 1,741 | 1,566 | Upgrade
|
| Revenue Growth (YoY) | 1.03% | 10.81% | 12.55% | 11.15% | -4.51% | Upgrade
|
| Cost of Revenue | 583.34 | 602.57 | 574.37 | 457.04 | 449.25 | Upgrade
|
| Gross Profit | 1,611 | 1,569 | 1,385 | 1,284 | 1,117 | Upgrade
|
| Selling, General & Admin | 888.26 | 920.66 | 812.68 | 722.13 | 628.74 | Upgrade
|
| Research & Development | 173.29 | 158.06 | 217.04 | 201.6 | 147.56 | Upgrade
|
| Other Operating Expenses | -23.52 | 27.43 | 36.09 | 32.8 | 30.4 | Upgrade
|
| Operating Expenses | 1,038 | 1,106 | 1,070 | 957.81 | 803.92 | Upgrade
|
| Operating Income | 572.63 | 462.87 | 315.65 | 326.37 | 313.31 | Upgrade
|
| Interest Expense | - | -16.36 | -20.24 | -18.21 | -11.55 | Upgrade
|
| Interest & Investment Income | 4.47 | 33.17 | 40.64 | 39.8 | 29.41 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0.08 | -3.59 | 0.57 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.97 | -0.34 | -0.58 | -1.23 | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | 583.07 | 479.27 | 331.89 | 347.31 | 331.05 | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.65 | 1.19 | 0.16 | 1.77 | -1.37 | Upgrade
|
| Gain (Loss) on Sale of Assets | 83.35 | 1.67 | 31.26 | 15.5 | - | Upgrade
|
| Asset Writedown | -27.13 | -0.17 | -1.02 | -8.12 | -1.71 | Upgrade
|
| Other Unusual Items | - | 36.31 | 83.89 | 72.61 | 16.2 | Upgrade
|
| Pretax Income | 643.93 | 518.28 | 446.18 | 429.06 | 344.17 | Upgrade
|
| Income Tax Expense | 122.4 | 96.99 | 116.65 | 85.34 | 67.14 | Upgrade
|
| Net Income | 521.53 | 421.3 | 329.53 | 343.72 | 277.02 | Upgrade
|
| Net Income to Common | 521.53 | 421.3 | 329.53 | 343.72 | 277.02 | Upgrade
|
| Net Income Growth | 23.79% | 27.85% | -4.13% | 24.08% | -29.36% | Upgrade
|
| Shares Outstanding (Basic) | 586 | 585 | 588 | 573 | 577 | Upgrade
|
| Shares Outstanding (Diluted) | 586 | 585 | 588 | 573 | 577 | Upgrade
|
| Shares Change (YoY) | 0.15% | -0.56% | 2.72% | -0.74% | -1.39% | Upgrade
|
| EPS (Basic) | 0.89 | 0.72 | 0.56 | 0.60 | 0.48 | Upgrade
|
| EPS (Diluted) | 0.89 | 0.72 | 0.56 | 0.60 | 0.48 | Upgrade
|
| EPS Growth | 23.61% | 28.57% | -6.67% | 25.00% | -28.36% | Upgrade
|
| Free Cash Flow | 506.16 | 472.85 | 466.4 | 266.15 | 392.52 | Upgrade
|
| Free Cash Flow Per Share | 0.86 | 0.81 | 0.79 | 0.47 | 0.68 | Upgrade
|
| Dividend Per Share | - | 0.600 | 0.800 | 0.900 | 0.400 | Upgrade
|
| Dividend Growth | - | -25.00% | -11.11% | 125.00% | 73.91% | Upgrade
|
| Gross Margin | 73.41% | 72.25% | 70.69% | 73.75% | 71.32% | Upgrade
|
| Operating Margin | 26.10% | 21.32% | 16.11% | 18.74% | 20.00% | Upgrade
|
| Profit Margin | 23.77% | 19.40% | 16.81% | 19.74% | 17.68% | Upgrade
|
| Free Cash Flow Margin | 23.07% | 21.77% | 23.80% | 15.29% | 25.06% | Upgrade
|
| EBITDA | 682.71 | 556.38 | 412.21 | 412.97 | 393.58 | Upgrade
|
| EBITDA Margin | 31.12% | 25.62% | 21.03% | 23.72% | 25.12% | Upgrade
|
| D&A For EBITDA | 110.08 | 93.51 | 96.55 | 86.6 | 80.27 | Upgrade
|
| EBIT | 572.63 | 462.87 | 315.65 | 326.37 | 313.31 | Upgrade
|
| EBIT Margin | 26.10% | 21.32% | 16.11% | 18.74% | 20.00% | Upgrade
|
| Effective Tax Rate | 19.01% | 18.71% | 26.15% | 19.89% | 19.51% | Upgrade
|
| Revenue as Reported | - | 2,172 | 1,960 | 1,741 | 1,566 | Upgrade
|
| Advertising Expenses | - | 514.72 | 361.86 | 378.93 | 64.35 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.